Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease

• Status: Completed
• Trial end date: 2018-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to assess safety and efficacy of DE-089 ophthalmic solution in patients with dry eye disease in Taiwan.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Santen Pharmaceutical Co., Ltd.
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• At least 6-month dry eye history

Exclusion Criteria:

• Diagnosed with Stevens-Johnson Syndrome or ocular pemphigoid

• Diagnosed with keratoconjunctival chemical burns or thermal burn

• Eye disease other than dry eye disease which needs treatment

• Allergic conjunctivitis that may possibly be aggravated during the clinical study and inappropriate for efficacy evaluation

• Those who need to wear contact lenses during the clinical study

• Those who are considered inappropriate for this study by the investigator or subinvestigators